Healthcare with Confidence
Immunotherapy for multiple myeloma is one of the most advanced and effective treatment approaches available in Israel today. These modern biological therapies activate the patient’s own immune system to recognize and destroy cancer cells, often with fewer side effects compared to traditional chemotherapy.
Israeli hematology centers use immunotherapy both as a standalone treatment and in combination with other therapies, tailoring each protocol to the individual patient.
What Is Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell responsible for producing antibodies. When plasma cells become malignant, they multiply uncontrollably and displace healthy blood-forming cells in the bone marrow. This disrupts the immune system and may cause anemia, bone damage, kidney problems, and infections.
Israel is internationally recognized for its expertise in hematologic cancers, including complex and advanced multiple myeloma.
Patients can receive a professional second opinion online, including treatment review, molecular testing recommendations, and personalized therapy planning.
Second Opinion from Leading Israeli Myeloma Specialists
⇒ Doctors for Myeloma – Consultation Online
Monoclonal Antibodies for Multiple Myeloma
Monoclonal antibodies target specific proteins on myeloma cells and either destroy them directly or stimulate the immune system to do so.
Key Antibody Therapies Used in Israel Today:
- Daratumumab (DARZALEX®)
Targets CD38 on myeloma cells. Proven effective in relapsed, refractory, and newly diagnosed myeloma, both alone and in combination therapies. - Daratumumab + Hyaluronidase (DARZALEX FASPRO®)
A subcutaneous formulation with shorter administration time and improved convenience. - Isatuximab (SARCLISA®)
Another CD38 antibody, commonly used in relapsed or resistant multiple myeloma. - Elotuzumab (EMPLICITI®)
Targets SLAMF7 (CS1). When combined with lenalidomide (Revlimid) and steroids, it improves disease control and survival in recurrent myeloma.
CAR-T Cell Therapy for Multiple Myeloma in Israel
CAR-T cell therapy is a breakthrough immunotherapy approved by the Israeli Ministry of Health after successful international trials.
- Patient’s own T cells are genetically modified to attack myeloma cells
- Highly effective in advanced and relapsed multiple myeloma
- Available in leading Israeli centers under strict medical supervision
- This treatment offers hope for patients who no longer respond to standard therapies.
Bone Marrow (Stem Cell) Transplantation
Autologous stem cell transplantation remains a cornerstone of multiple myeloma treatment in eligible patients. In Israel, it is often combined with:
- Immunotherapy
- Proteasome inhibitors
- Precision medicine strategies
Antibody-Drug Conjugates
- Belantamab mafodotin-blmf (BLENREP®)
A targeted antibody delivering chemotherapy directly to myeloma cells, minimizing systemic toxicity.
Advanced Targeted and Immunological Treatments
Immunomodulatory Drugs (IMiDs):
- Lenalidomide (Revlimid)
- Pomalidomide (Pomalyst)
- Thalidomide
Proteasome Inhibitors:
- Bortezomib (Velcade)
- Carfilzomib (Kyprolis)
- Ixazomib (Ninlaro)
Other Targeted Therapies:
- Selinexor (EXPOVIO®) – XPO1 nuclear export inhibitor
- Panobinostat (FARYDAK®) – HDAC inhibitor
Precision (Personalized) Treatment for Multiple Myeloma
Israeli hematologists widely use molecular and genetic testing to build a genomic profile of the tumor. This allows doctors to:
- Predict drug response
- Avoid ineffective treatments
- Reduce toxicity
- Improve long-term outcomes
Personalized immunotherapy is especially important for relapsed, refractory, or high-risk multiple myeloma.
Chemotherapy Drugs Used When Needed
While immunotherapy has transformed treatment, chemotherapy may still play a role in selected cases:
- Bendamustine (Treanda)
- Cyclophosphamide (Cytoxan)
- Doxorubicin / Liposomal Doxorubicin (Adriamycin, Doxil)
- Melphalan
- Etoposide (VP-16)
- Vincristine (Oncovin)
Clinical Trials and New Immunotherapies
Israel actively participates in international clinical trials, including:
- New CAR-T platforms
- Bispecific antibodies (BCMA-directed therapies)
- Immune checkpoint inhibitors
- Therapeutic vaccines
These trials provide access to next-generation treatments, even for newly diagnosed patients.
Why Choose Israel for Multiple Myeloma Immunotherapy?
- World-renowned hematologists
- Access to the newest FDA- and EMA-approved drugs
- Personalized treatment strategies
- Advanced CAR-T and stem cell programs
- Online consultations and second opinions available
Schedule a Consultation with a Leading Israeli Hematologist
